CompletedNCT00090311
Quetiapine for mania in children and adolescents with bipolarity
About this title
Read the official source — NCT00090311This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Medication studyAges 10–17United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Scottsdale and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 220
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00090311
- Official title
Show the full official title
A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale · Riverside · Sacramento
29 more locations
- San Diego
- Denver
- Alamonte
- Jacksonville
- Miami
- Augusta
- Chicago
- Wichita
- New Orleans
- Saint Charles
- Las Vegas
- Clementon
- Piscataway
- Rochester
- Chapel Hill
- Cincinnati
- Cleveland
- Lyndhurst
- Oklahoma City
- Philadelphia
- Madison
- Austin
- Houston
- San Antonio
- Richmond
- Virginia Beach
- Bellevue
- Kirkland
- Milwaukee
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
